Skip to main content


Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia


Alzheimer’s disease (AD)-related amyloid β-peptide (Aβ) pathology in the form of amyloid plaques and cerebral amyloid angiopathy (CAA) spreads in its topographical distribution, increases in quantity, and undergoes qualitative changes in its composition of modified Aβ species throughout the pathogenesis of AD. It is not clear which of these aspects of Aβ pathology contribute to AD progression and to what extent amyloid positron emission tomography (PET) reflects each of these aspects. To address these questions three cohorts of human autopsy cases (in total n = 271) were neuropathologically and biochemically examined for the topographical distribution of Aβ pathology (plaques and CAA), its quantity and its composition. These parameters were compared with neurofibrillary tangle (NFT) and neuritic plaque pathology, the degree of dementia and the results from [18F]flutemetamol amyloid PET imaging in cohort 3. All three aspects of Aβ pathology correlated with one another, the estimation of Aβ pathology by [18F]flutemetamol PET, AD-related NFT pathology, neuritic plaques, and with the degree of dementia. These results show that one aspect of Aβ pathology can be used to predict the other two, and correlates well with the development of dementia, advancing NFT and neuritic plaque pathology. Moreover, amyloid PET estimates all three aspects of Aβ pathology in-vivo. Accordingly, amyloid PET-based estimates for staging of amyloid pathology indicate the progression status of amyloid pathology in general and, in doing so, also of AD pathology. Only 7.75% of our cases deviated from this general association.


The deposition of amyloid β-peptide (Aβ) in amyloid plaques is one of the histopathological hallmark lesions of Alzheimer’s disease (AD) [47] together with neurofibrillary tangles (NFTs) [35]. Neuritic plaques represent a subset of the Aβ plaques characterized by the presence of dystrophic neurites in the plaques that can be stained with antibodies against abnormal τ-protein [11, 18, 35, 51, 70]. In addition to its presence in amyloid plaques, Aβ can also be found in cerebral and leptomeningeal blood vessels affected by cerebral amyloid angiopathy (CAA) [25], as soluble, dispersible Aβ in extra- or intracellular fluid, and as membrane-associated Aβ aggregates [14, 29, 56, 58, 81]. Aβ pathology can be described by 1. the topographical distribution of Aβ plaques [11, 71, 72] or CAA-affected vessels in the brain [68], 2. measures of quantity in a given brain region (morphological Aβ plaque loads, biochemically detected measures of Aβ levels (ELISA, western blotting)) [2, 3, 14, 41, 46, 50, 57, 59, 81], and 3. qualitative changes in the composition of detectable modified and non-modified Aβ species, such as Aβ40/42, AβN3pE and AβpSer8 [4, 24, 38, 44, 57, 61, 75]. Aβ aggregation, thereby, starts with the accumulation of amyloid fibrils that are only detectable with antibodies detecting non-modified forms, followed by the presence of AβN3pE and finally by AβpSer8, indicating a process called “maturation of Aβ aggregates” [75]. However, it is not yet clear to what extent a) the different aspects of Aβ pathology, i.e. the topographical distribution of plaques and CAA-affected vessels, the quantitative and qualitative measures of Aβ aggregation and deposition, correlate with one another, b) predict the development of dementia and c) can be estimated in-vivo by amyloid PET.

To address these questions, three cohorts of autopsy cases were neuropathologically analyzed for the topographical distribution of Aβ plaques and CAA. These parameters were correlated with the clinical degree of dementia and neuropathological measures for NFT and neuritic plaque pathology in all three cohorts, quantitative measures for plaque loads in two cohorts, biochemically detected levels of Aβ in one cohort, the morphologically and biochemically determined stages of Aβ aggregates maturation in one cohort, and with the [2] flutemetamol PET estimates for the phase of Aβ plaque deposition in another cohort.

Material and methods


The findings of 3 cohorts of autopsy cases (Table 1) were combined where possible and reassessed. The first cohort of 95 cases represents autopsy cases from university and municipal hospitals in Bonn, Ulm and Offenbach am Main (Germany) [57, 71, 73], a second novel cohort of 79 cases represents cases from the university hospital in Leuven (Belgium), and the third cohort of 97 cases was included in the efficacy analysis of the [18F] flutemetamol phase III autopsy study ( identifiers NCT01165554, and NCT02090855) [9, 36]. Local institutional review boards or ethics committees approved the study protocols before initiation [17, 66]. This study covering samples from three cohorts was approved by the UZ/KU-Leuven ethical committee (S-59295).

Table 1 Age, gender distribution of the 3 patient cohorts and the respective distribution of Aβ phases, Aβ-MTL phases, A-scores, Braak NFT-stage, CERAD neuritic plaque score, NIA-AA degree of AD pathology, diagnosis, PET-Aβ phase estimate, B-Aβ stage, B-Aβ plaque stage, Aβ load. Short description of the recruitment criteria of the cohorts and case selection criteria for this study

The non-AD and pathologically diagnosed preclinical cases with AD pathology (p-preAD) [57] of cohorts 1 and 2 were examined at the time point of hospital admission (approximately 1 to 4 weeks prior to death) by clinicians with different specialties according to standardized protocols. The AD patients were diagnosed by a neurologist (RV, MV, MO, CAFvA) and followed until death. The protocols included the assessment of cognitive function (orientation to place, time and person; specific cognitive or neuropsychiatric tests were not performed) and recorded the patients’ ability to care for themselves and to get dressed, eating habits, bladder and bowel continence, speech patterns, writing and reading ability, short-term and long-term memory, and orientation within the hospital setting. These data were used to retrospectively assess the clinical dementia rating (CDR) scores for 162/174 patients [34] without knowledge of the pathological diagnosis. For this purpose, the information from the clinical files was used to provide a CDR score according to the standard CDR protocol [34]. For 12 cases of cohorts 1 and 2 the clinical data were not sufficient to obtain a CDR score retrospectively. In cohort 3, the clinical data provided mini-mental state examination (MMSE) [23] test results from 65 cases.


Autopsy was performed with informed consent of the patients during life or the next in kin after death of the patient. From cohorts 1–3 one brain hemisphere was cut fresh and specimens were kept frozen for biochemical analysis. The other hemisphere was fixed in a 4% aqueous solution of formaldehyde (cohort 1) or phosphate buffered formaldehyde (cohorts 2–3) for ca. 3–4 weeks before cutting. In the event that tissue was considered as suspicious for Creutzfeldt-Jakob disease no frozen tissue was collected and the formalin-fixed tissue was decontaminated in 99% formic acid. Brains were cut in coronal slices and screened macroscopically. For histopathological analysis and for assessing the amounts of AD-related amyloid plaques, NFTs, and neuritic plaques, paraffin-embedded tissue including parts of the frontal, parietal, temporal, occipital cortex, and entorhinal cortex, the hippocampal formation at the level of the lateral geniculate body, basal ganglia, thalamus, amygdala, midbrain, pons, medulla oblongata and cerebellum were examined. Paraffin sections of 5–12 μm thickness from all blocks were stained with hematoxylin & eosin. For neuropathological diagnosis sections were stained with the Gallyas (cohort 1) or Bielschowsky (cohort 3) silver method and immunohistochemical methods (cohorts 1–3) with primary antibodies against abnormal phosphorylated τ protein (p-τ), Aβ17–24, AβN3pE, AβpSer8 [40], phosphorylated transactive DNA-binding protein TDP43 (pTDP43), α-synuclein, and/or ubiquitin as listed in Additional file 1: Table S1. Primary antibodies were detected with biotinylated secondary antibodies and visualized with the DABMap Kit (Ventana, USA) or with diaminobencidine-HCl and the avidin-biotin complex (Vector, USA).

The phase of Aβ plaque pathology (Aβ phase) was assessed after screening the Aβ-stained sections for plaque distribution according to previously published protocols (Additional file 1: Table S2). One single amyloid plaque, thereby, indicated that a given anatomical brain region was considered as amyloid positive [1, 71]. The neuropathological diagnosis of AD pathology as well as the assessment of the A-score (A0 – A3) for amyloid plaque distribution and the determination of the NIA-AA degree of AD pathology was performed as recommended [35] (Additional file 1: Table S2). Braak-NFT staging was performed based on sections stained with an antibody against abnormal τ-protein (AT8, Additional file 1: Table S1) according to a widely accepted protocol in all cohorts [10]. In some cohort 1 cases, Braak NFT-staging was confirmed with the Gallyas silver staining method [11]. The consortium to establish a registry for AD (CERAD) scores for neuritic plaque density were assessed based on sections stained with an antibody against abnormal τ-protein (AT8, Additional file 1: Table S1) [51].

As an additional staging strategy for the topographical distribution of Aβ plaques we used the phases of Aβ plaque distribution in the medial temporal lobe (AβMTL phases) [72]. The assessment of the Aβ phases, A-scores, and AβMTL phases was carried out according to the protocol depicted in Additional file 1: Table S2a-d. In addition, the severity of CAA according to Vonsattel [80], and the stage of topographical expansion of CAA have been assessed as previously described [68] (for details see Additional file 1: Table S2e,f).

To assess the quantitative aspect of Aβ pathology, Aβ-loads were determined in all cases of cohort 1 and in 31 cases of cohort 3 as the percentage of the area in the temporal neocortex (Brodmann area 36) covered by Aβ plaques detected with anti-Aβ17–24. Morphometry for Aβ load determination in cohort 1 was performed using ImageJ image processing and analysis software (National Institutes of Health, Bethesda, USA). For plaque measurements, the area of the morphologically identified plaques was interactively delineated with a cursor and then measured. Neuronal staining by the anti-Aβ17–24 antibody was considered as cross-reactivity with amyloid precursor protein (APP) and not included for the assessment of the Aβ load. The areas of all plaques in a given cortical region were added up. The area of the respective cortex areas was likewise measured by interactive delineation with a cursor. The Aβ load was calculated as the percentage of the area of interest covered by Aβ plaques [56]. Likewise, AβN3pE and AβpSer8 loads were assessed in 70 cases of cohort 1 cases. In cohort 3 the cortical Aβ loads were assessed in the middle temporal gyrus after scanning the 4G8-stained sections with a slide scanner and performing automated analysis of cortical regions of interest with Aperio XT software and a pre-developed macro (MATLAB, Math Work In, MA, USA) [36]. Thresholds for intensity, size, and morphometry were set by the macro to distinguish Aβ plaques from non-plaque related neuronal APP staining after color deconvolution to remove the hematoxylin staining channel. These Aβ load measures for cohort 3 were performed at a single laboratory to ensure consistency. The investigators were blinded to clinical and imaging data and to the results of other histopathology analyses.

To document qualitative changes in the aggregate composition, the stage of maturation of Aβ plaques (B-Aβ plaque stage) was determined in 70 cases of cohort 1 (Tab. 1) [57]. To do so, sections were immunostained with antibodies raised against Aβ17–24, AβN3pE, and AβpSer8. Four B-Aβ plaques stages were distinguished (for details see Additional file 1: Table S3a).


Biochemical analysis was carried out from 38 cases of cohort 1 (Tab. 1) [57]. Protein extraction from fresh frozen occipital and temporal neocortex (0.4 g) was carried out in 2 ml of 0.32 M sucrose dissolved in Tris-buffered saline (TBS) containing a protease and phosphatase inhibitor-cocktail (Complete and PhosSTOP, Roche, Mannheim, Germany). The tissue was first homogenized with Micropestle (Eppendorf, Hamburg, Germany) followed by sonication (Sonoplus HD 2070, Heidolph instruments, Germany). The homogenate was centrifuged for 30 min at 14000 x g at 4 °C. The supernatant (s1) was ultracentrifuged to at 175000 x g to separate the soluble fraction (supernatant s2) and the dispersible fraction (pellet p2). The pellet (p2) resuspended in TBS and the supernatant as the soluble fraction (s2) were stored at − 80 °C until further use, respectively. The pellet (p1) containing the membrane-associated and the solid plaque-associated fraction was resuspended in TBS containing 2% sodium dodecyl sulfate (SDS) was centrifuged at 14000 x g. The supernatant (s3) was kept as membrane-associated SDS soluble fraction. The pellet (p3) was further dissolved in 70% formic acid and the homogenate was lyophilized by centrifuging in the vacuum centrifuge (Vacufuge; Eppendorf, Germany) and reconstituted in 100 μl of 2X lithium dodecyl sulfate (LDS) sample buffer (Invitrogen, Carlsbad, CA, USA) followed by heating at 70 °C for 5 min. The resultant sample was considered as plaque-associated, formic acid-soluble fraction [48]. The total protein contents of soluble, dispersible, and membrane-associated fractions were determined using BCA Protein Assay (Bio-Rad, Hercules, CA, USA).

For western blot analysis, the four fractions (soluble, dispersible, membrane-associated and plaque-associated) were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent western blot analysis with anti-Aβ1–17, anti-AβN3pE and anti-AβpSer8 antibodies (Additional file 1: Table S1). Blots were developed with an ECL detection system (Supersignal Pico Western system, ThermoScientific-Pierce, Waltham, MA, USA) and illuminated in ECL Hyperfilm (GE Healthcare, Buckinghamshire, UK). For semiquantitative comparison of optical densities of the 4 kDa Aβ bands were measured using ImageJ software (NIH, Bethesda, USA) as previously described [56].

The biochemical stages of Aβ aggregation (B-Aβ stages) were determined by the detection of the presence/absence of Aβ, AβN3pE, and AβpSer8 in at least one of the four fractions according to a previously published protocol (for detail see Additional file 1: Table S3b) [57].

[18F]Flutemetamol PET image assessments

Amyloid PET imaging was performed for the cases in cohort 3 at 12 different imaging sites [62, 66]. Before PET imaging, subjects underwent head CT or magnetic resonance imaging (MRI), unless prior images (obtained within 12 months) were available. [18F]Flutemetamol injection was administered intravenously at a dose of 185 or 370 MBq of radioactivity at physician discretion [66]. PET images were acquired in 2.5-min frames on PET/CT cameras, beginning approximately 90 min post injection, which was attenuation corrected using CT data. Frame to frame motion correction was performed on the dynamic data before the frames were averaged to give a 10-min scan. Equipment used to capture images varied across the 12 imaging sites [66]. Most images were reconstructed iteratively to form 128 × 128 axial slices, and a Gaussian post-reconstruction smoothing filter was applied to some to achieve uniform image resolution across sites.

[18F]flutemetamol uptake was measured for six volumes of interest (VOIs) restricted to gray matter and adjusted for atrophy manually where possible, covering anterior cingulate, prefrontal cortex, lateral temporal cortex, parietal cortex, one VOI covering both posterior cingulate and precuneus, and one subcortical VOI in the head of the caudate nucleus according to Thal et al. [67] and Beach et al. [9]. Quantitative standardized uptake value ratio (SUVR) calculations were made using pons as reference region [76]. A global cortical average (neocortical (composite) SUVR (SUVRneo); obtained from anterior cingulate, prefrontal, lateral temporal, parietal, and posterior cingulate cortex including the precuneus region) was calculated [79]. The SUVR for the caput nuclei caudati (SUVRcaud) was determined based on VOI measurements of both the left and right caudate nucleus (anterior aspect). The caudate VOIs were drawn on a parasagittal plane which intersected the thalamus, internal capsule, caudate head and frontal white matter (manually due to the lack of structural MRI for most cases). Image processing and VOI analysis was performed using VOIager 4.0.7 (GE Healthcare, Uppsala, Sweden) [67].

Thresholds to distinguish Aβ phases by [18F] flutemetamol PET based estimates were applied as recently published (for detail see Additional file 1: Table S4) [67].

Statistical analysis

Spearman correlation, partial correlation, linear regression analysis and regression coefficients were calculated using SPSS 25 statistical software (IBM, Armonk, NY, USA). To exclude collinearity with age and sex when comparing Aβ-related parameters with non-Aβ-related parameters partial correlation and regression analyses were controlled for age and sex. For comparisons of the different aspects of Aβ pathology with one another the Spearman correlation analysis was used without controlling for age and sex in order not to bias these comparisons of different aspects of aggregates of the same molecule by including additional independent variables in the respective model terms. The Friedman test was used to compare Aβ, AβN3pE, and AβpSer8 in dependent samples to observe differences in the respective levels and loads. Pairwise comparisons were adjusted for multiple testing according to the Bonferroni method.


The main findings of this study were (1) strong correlations between the topographical (Aβ phases, AβMTL phases, A-scores, CAA stages, and CAA-severity), quantitative (Aβ loads, Aβ levels determined biochemically in cortical brain homogenates), and qualitative (B-Aβ stages for Aβ aggregate/Aβ plaque maturation) aspects of Aβ pathology, (2) estimation of these aspects by the SUVR-based PET-Aβ phase estimates, and (3) its relationship with preclinical and symptomatic stages of AD and cognitive decline.

Correlations between topographical, quantitative and qualitative aspects of Aβ pathology

Spearman correlation analysis was applied to determine correlations between topographical (Aβ phases, AβMTL phases, A-scores, CAA stage, and CAA severity), quantitative (Aβ, AβN3pE, and AβpSer8 loads, biochemically detected levels of soluble, dispersible, membrane-associated and plaque-associated Aβ, AβN3pE, and AβpSer8), and qualitative Aβ parameters (B-Aβ stages, and B-Aβ plaque stages) in cohort 1. This analysis revealed strong correlations between these parameters (Additional file 1: Table S5a). The AβpSer8 levels in the plaque-associated fraction did not correlate with the B-Aβ plaque stage (p = 0.094; Additional file 1: Table S5a). Soluble AβpSer8 was not detectable. The correlations between topographical parameters (Aβ phases, AβMTL phases, A-scores, CAA stage, and CAA severity) were confirmed in cohorts 2 and 3 (Additional file 1: Table S5b). The correlation of topographical parameters with Aβ load was confirmed in cohort 3 (Additional file 1: Table S5c).

In detail, with increasing Aβ phase, AβMTL phase, and A-score, the Aβ load increased showing in general higher levels than the AβN3pE load and the AβpSer8 load (Fig. 1a-c; Friedman test corrected for multiple testing: p = 0.001). Increased AβpSer8 loads were mainly restricted to end stages (Aβ phases 4 and 5, AβMTL phase 4, and A-score 3) and lower than AβN3pE loads (Fig. 1a-c; Friedman test corrected for multiple testing: p < 0.001). Cases without CAA but with Aβ and AβN3pE loads larger than 0 were seen with Aβ loads ranging from 0.02 to 9.78% (cohort 1)/ 0.017 to 17.625% (cohort 3) with a mean of 3.068% (cohort 1)/ 7.17% (cohort 3) (Fig. 1d, e). In general, Aβ, AβN3pE, and AβpSer8 loads increased with advancing topographical expansion of CAA pathology over the brain (represented by the CAA stage), and with increasing destruction of the vessel wall of cortical and leptomeningeal blood vessels by Aβ deposits (represented by the CAA severity) (Fig. 1d, e). AβpSer8 was thereby, seen in cases with CAA stage 2 and CAA severity degree 2.

Fig. 1

Comparison of the relationship of the Aβ phases (a), AβMTL phases (b), the A-scores (c), CAA stages (d) and CAA severities (e) with Aβ plaque loads for Aβ, AβN3pE, and AβpSer8-containig plaques in cohort 1, depicted by boxplot diagrams. a: The plaque-loads for Aβ (Spearman correlation analysis: r = 0.888) and AβN3pE (Spearman correlation analysis: r = 0.882) correlated better with the Aβ phases than that for AβpSer8-positive plaques (Spearman correlation analysis: r = 0.810). b-e: Likewise, the AβMTL phases (b), the A-scores (c), the CAA stage (d) and the CAA severity (e) correlated with the Aβ, AβN3pE, and AβpSer8 loads (r = 0.582–0.899; p < 0.001; for detailed statistical analysis see Additional file 1: Table S5a)

A similar correlation relation was observed for the biochemically detected levels of soluble, membrane-associated and plaque-associated Aβ, AβN3pE, and AβpSer8 increasing with the five topographical parameters for Aβ pathology, except for soluble AβpSer8 (Fig. 2), which was not detected in these cases. The levels of soluble, dispersible, membrane-associated, and plaque-associated total Aβ were higher than that of the respective levels of AβpSer8 (Fig. 2; Friedman test corrected for multiple testing: p < 0.001–0.025). Eight cases without CAA showed Aβ and AβN3pE mainly in the membrane-associated and the plaque-associated fraction. The levels of Aβ, AβN3pE, and AβpSer8 increased in CAA stage 1 and remained similar in stage 2. Biochemical data from CAA stage 3 cases were not available for this analysis. A similar pattern was observed for the severity degree of CAA. There was an increase until CAA severity degree 1 (mild CAA). In CAA severity degree 2 and 3 cases, similar levels of soluble, dispersible, membrane-associated and plaque-associated Aβ, AβN3pE, and AβpSer8 were observed (Fig. 2).

Fig. 2

Boxplot diagrams representing the distribution of soluble (Sol.), dispersible (Disp.), membrane-associated (Memb. ass.), and plaque-associated (Plaq. Ass.) Aβ (a, d, g, j, m), AβN3pE (b, e, h, k, n), and AβpSer8 levels (c, f, i, l, o) in relation to the phase of Aβ plaque distribution (Aβ phase; a-c), the AβMTL phase (d-f), the A-score (g-i), the CAA stages (j-l) and the CAA severity (m-o) in cohort 1. The correlation for these three different forms of Aβ was best for Aβ detected with antibodies against non-modified forms of Aβ (Spearman correlation analysis: r = 0.603–0.809) followed by AβN3pE (Spearman correlation analysis: r = 0.572–0.756) whereas AβpSer8 was not detectable in soluble Aβ aggregates. Dispersible, membrane-associated and plaque-associated AβpSer8 showed a week correlation with the Aβ phases (Spearman correlation analysis: r = 0.324–0.556) due to the fact that it was seen only in Aβ phases 4 and 5 but not earlier, except for single cases. Increased levels of Aβ and AβN3pE were found already in cases without CAA (m, n). Cases with CAA showed high levels of soluble, dispersible, membrane-associated, and plaque-associated Aβ and AβN3pE in all stage and severity degrees of CAA. Only the presence of AβpSer8 was restricted to cases with CAA. The detailed correlation analysis is provided in Additional file 1: Table S5a

The qualitative changes in the composition of Aβ aggregates over time as represented by the B-Aβ stages and B-Aβ plaques stages progressed with increasing Aβ phase, AβMTL phase and A-score (Fig. 3a-c). With respect to the Aβ phases the last stage of Aβ aggregate maturation was reached in nearly all Aβ phase 4 cases and remained stable in Aβ phase 5 (Fig. 3a). Such a saturation effect was not that apparent when studying the B-Aβ and B-Aβ plaque stages in relation to the AβMTL phases and the A-scores (Fig. 3b, c). Most cases with CAA (CAA stage 1–3, CAA severity degree 1–3) showed B-Aβ stage 3 (66.7%) and B-Aβ plaque stage 3 (87.1%) (Fig. 3d, e).

Fig. 3

Boxplot diagram comparing the relationship of the Aβ phases (a), AβMTL phases (b), A-scores (c), CAA stages (d) and CAA severities (e) with the biochemical stages of Aβ aggregate maturation reflecting the hierarchical occurrence of Aβ, AβN3pE, and AβpSer8 in Aβ aggregates in brain homogenates (B-Aβ stages) or in Aβ plaques (B-Aβ plaque stage) in cohort 1. a: The B-Aβ stages and the B-Aβ plaque stages increased with increasing Aβ phase until Aβ phase 4 when the maximum B-Aβ and B-Aβ plaques stages were reached. b, c: AβMTL phases and A-scores also correlated with the B-Aβ stages and B-Aβ plaque stages but exhibiting no ceiling effect. d, e: In the presence of CAA regardless of the stage (d) or severity (e), end-stage B-Aβ stage and B-Aβ plaque stage were observed, probably indicative for a ceiling effect. (Spearman correlation analysis: r = 0.694–0.906) (for detailed statistical analysis see Additional file 1: Table S5a)

Correlations of PET-Aβ phase estimates with topographical parameters of Aβ pathology and Aβ load

In the cases from cohort 3 we compared the different topographical parameters for Aβ pathology (Aβ phase, AβMTL phase, A-score, CAA stage and CAA severity) as well as the quantitative measure of the Aβ load among the PET-Aβ phase estimates obtained in patients 0–846 (mean 215) days before death and subsequent autopsy. All topographical parameters of Aβ pathology as well as the Aβ load correlated with the PET-Aβ phase estimates with r ranging from 0.610 to 0.835 (Spearman correlation analysis: p < 0.001) (Additional file 1: Table S6).

Of the 20 amyloid PET-negative cases (PET-Aβ phase estimate 0), 13 showed plaque pathology whereas CAA was found only in four of them. With increasing PET-Aβ phase estimate the Aβ phases increased (Fig. 4a). AβMTL phase, A-score, CAA stage and CAA severity also gradually increased until PET-Aβ phase estimate 2 reaching a plateau that is also seen in cases with PET-Aβ phase estimate 3. Of note, CAA stage remained stable at the second stage while the third CAA stage was limited to single cases with PET-Aβ phase estimates ranging from 0 to 3. For CAA severity only one case with PET-Aβ phase estimate 3 exhibited CAA-related bleedings eligible for severity degree 3 (Fig. 4a). The Aβ load also gradually increased with increasing PET-Aβ phase estimate becoming detectable with a median Aβ load of 1.42% in PET-Aβ phase estimate 1 (Fig. 4b).

Fig. 4

Boxplot diagrams representing the distribution of Aβ phase, AβMTL phase, A-score, CAA stage, CAA severity (a) and Aβ loads (b) in relation to the PET-Aβ phase estimate in cohort 3. All parameters correlated with the PET-Aβ phase estimates (r = 0.610–0.835; p < 0.001; for detailed statistical analysis see Additional file 1: Table S6). Note that the main increase in Aβ load occurs after Aβ became detectable in PET-Aβ phase estimate 1. The mean value of the Aβ load in PET-Aβ phase estimate 1 was 1.396% (median 1.42%) indicative for the threshold of Aβ detectability in the brain by PET

Correlations of topographical, quantitative and qualitative Aβ parameters with the degree of dementia and non-Aβ AD pathology

To determine the relationship of the different aspects of Aβ pathology with NFT pathology, neuritic plaques, AD pathology in general and the degree of dementia, we performed partial correlation analysis controlled for age and sex. The topographical and qualitative Aβ parameters as well as the Aβ, AβN3pE, and AβpSer8 load correlated with Braak NFT stages, CERAD scores, NIA-AA degrees of AD pathology, and the degree of dementia measured by the CDR score or the MMSE score, respectively (Fig. 5a-l, Additional file 1: Table S7a-c). The biochemically measured levels of soluble, dispersible, membrane-associated, and plaque associated Aβ, AβN3pE, and plaque-associated AβpSer8 also correlated with increasing Braak NFT stages, CERAD scores, and NIA-AA degrees of AD. However, only soluble, dispersible, plaque-associated AβN3pE, and plaque-associated AβpSer8 correlated with the CDR score whereas the biochemical levels of non-modified forms of Aβ did not correlate with increasing dementia represented by the CDR score (Fig. 5, Additional file 1: Table S7). The B-Aβ stage and the B-Aβ plaque stages representing qualitative changes in Aβ aggregates/ plaque composition over time correlated with Braak NFT stages, CERAD scores, NIA-AA degrees of AD pathology and CDR-scores indicating that the presence of post-translationally modified forms of Aβ is associated with cognitive decline and AD pathology progression (Fig. 5m, Additional file 1: Table S7a).

Fig. 5

Boxplot and scatter diagrams depicting the correlation of the Braak NFT stages, CERAD-scores for neuritic plaque pathology, NIA-AA scores of AD pathology, and the clinical dementia scores (CDR for cohorts 1 and 2 and MMSE for cohort 3) with the topographical Aβ parameters Aβ phase (a-d) and CAA stage (e-h), the quantitative measure of the Aβ load (i-l), and the qualitative aspect provided by the B-Aβ plaque stages (m). The boxplots are depicted separately for cohorts 1 (a, e, i, k, m), 2 (b, f), and 3 (c, d, g, h, j, l). The Braak NFT stages, CERAD scores, NIA-AA degrees of AD pathology, and CDR scores correlated with all parameters depicted here (r = 0.287–0.920, p < 0.001). Likewise, the MMSE scores showed a negative correlation with the Aβ phase and the CAA stages in cohort 3 (r = − 0.514/− 0.315, p ≤ 0.012) except for the Aβ load (p = 0.051) which showed only a trend (for detailed statistical analysis see Additional file 1: Table S7)

A few cases did not follow the general correlation between Aβ and NFT pathology. Sixteen cases showed widespread amyloid plaque pathology with Aβ phases 4 and 5 but only low Braak NFT stages (0-II). Another 4 cases exhibited severe NFT pathology (Braak NFT stage IV-V) with negligible plaque pathology (Aβ phases 0–2). Moreover, severe CAA without large numbers of plaques or NFTs was seen in one case of cohort 3 (Braak NFT stage 0, amyloid phase 3, CAA stage 3). Altogether, 21 of 271 cases (7.75%) did not follow the general correlation.

The PET-Aβ phase estimates as an Aβ topography-related parameter that can be measured in patients correlated with Braak NFT stage, CERAD scores and NIA-AA degrees of AD pathology and with decreasing MMSE scores indicating a correlation with cognitive decline (Additional file 1: Table S7c). All cases with PET-Aβ phase estimates between 2 and 3 with known MMSE scores showed at least mild cognitive impairment (MMSE score 27 or lower) with a median of 3 (mean = 5.19) and a range between 0 and 27. Except for one case with vascular dementia (NIA-AA score 1, Braak NFT stage 3, Aβ phase 3) all other cases (39 out of 40 cases) fulfilled the criteria of intermediate to severe AD pathology (NIA-AA scores 2 and 3). PET-Aβ phase estimate 1 cases consisted of a heterogeneous group with MMSE scores ranging between 0 and 30 (median: 7; mean = 9.71). The NIA-AA degree of AD pathology was low (1) in 70% of the PET-Aβ phase 1 cases and intermediate (2) in 30%. Those cases with NIA-AA scores of 2 were demented due to AD whereas the cases with NIA-AA scores of 1 were either normal or had dementia due to Lewy body disease or vascular dementia. The neuropathologically normal case with low NIA-AA degree of AD pathology and cognitive deficits was reported to be terminally ill (scan-death interval: 9 days), which may explain the low performance in the MMSE test. The 20 cases with a negative [18F]flutemetamol PET were either normal (n = 7) or had a non-AD dementia (Lewy body disease (n = 3), vascular dementia (n = 6), neurofibrillary predominant dementia (n = 1), argyrophilic grain disease (n = 1), progressive supranuclear palsy (n = 1), and frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) (n = 1)). The MMSE scores (available in 15 of these cases) ranged between 0 and 30 with a median of 15 (mean = 15.15). AD pathology was either absent or low, except for the one case with FTLD-TDP with an intermediate degree of AD pathology.


The results of this study demonstrate that topographical, quantitative and qualitative aspects of Aβ pathology correlated with one another. The advancing Aβ pathology detected neuropathologically in autopsy brains correlated well with the increase of [18F]flutemetamol PET-derived PET-Aβ phase estimates, i.e. with a staging system based upon amyloid PET-derived SUVR-thresholds applicable in patients during life [67]. All different aspects of Aβ pathology also correlated with increasing non-Aβ AD neuropathology, i.e. Braak NFT stages and CERAD scores for neuritic plaques detected with an antibody raised against p-τ. The NIA-AA score of AD pathology as a global parameter for AD pathology linking Aβ and p-τ lesions and the degree of dementia correlated with increasing topographical, quantitative, and qualitative aspects of Aβ pathology. Biochemically, the levels of post-translationally modified forms of Aβ pathology, i.e. AβN3pE and AβpSer8, correlated with the increasing degree of dementia as represented by the CDR score but not with the levels of non-modified Aβ. This argues in favor of the hypothesis that qualitative changes in Aβ aggregate composition, i.e. Aβ aggregate maturation due to posttranslational modifications of Aβ, are critical in the progression of AD. This maturation of Aβ aggregates in plaques also correlated with the frequency of neuritic plaques (Additional file 1: Table S7a), i.e. the development of amyloid plaques associated with p-τ-containing dystrophic neurites. These findings are in line with previous reports showing a stepwise progression of Aβ aggregate maturation in AD, CAA, and Down-syndrome [4, 24, 44, 57] as well as with studies indicating the aggregation prone effects of AβN3pE and AβpSer8 [55, 63].

Our results are in line a) with previous studies showing correlations between Aβ plaque loads, qualitative changes in Aβ aggregate composition and the topographical distribution of Aβ plaque pathology [3, 57, 75], b) with the association of the respective Aβ parameters with NFT and neuritic plaque pathology and c) with the degree of dementia when including non-AD control, preclinical and symptomatic AD cases [11, 12, 54, 69, 71,72,73]. Although the degree of dementia has been reported to correlate better with NFT pathology in AD cases rather than with Aβ plaque pathology [2], it became clear that Aβ pathology has already reached high levels when AD becomes symptomatic while NFT pathology did not [30, 71, 73]. The correlation of AD progression with increasing tracer retention in amyloid PET seen in our study is in line with other studies [15, 17, 31, 52, 60].

In contrast to previous studies, we correlated all aspects (topography, quantity and quality) of Aβ pathology in one cohort, confirmed the relationship between topographical aspects of Aβ pathology with p-τ pathology in NFTs, neuritic plaques and the cognitive status of the patients in two additional cohorts. Based on our findings the assessment of the Aβ phases already provides sufficient information to estimate the quantity of Aβ plaques, their maturation status, the frequency of neuritic plaques, the severity of CAA, and the topographical expansion of NFTs in more than 90% of the cases. Accordingly, the PET-Aβ phase estimates as an in-vivo parameter represent distinct steps of the underlying neuropathological and biochemical progression of Aβ pathology. Since changes in Aβ biomarkers, including those observed with amyloid PET, precede that of p-τ biomarkers [13, 30] and since PET-Aβ phase estimates allow prediction of the underlying neuropathological phase of Aβ deposition [67] our current findings strongly argue in favor of using amyloid PET and its derived PET-Aβ phase estimates as markers for AD pathology in general and for disease monitoring once the diagnosis of AD has been established in a given individual.

Although our results demonstrate strong correlations among the AD-related neuropathological and biochemical parameters studied here, there are some exceptional cases with discrepancies among the aspects of Aβ and AD pathology: Severe CAA without large numbers of plaques or NFTs was seen in one case of cohort 3 (Braak NFT stage 0, amyloid phase 3, CAA stage 3); widespread amyloid plaques (Aβ phases 4 and 5) but only limited NFT pathology (Braak NFT stage 0-II) was observed in 16 cases; and severe NFT pathology (Braak NFT stage IV-V) with negligible plaque pathology (Aβ phases 0–2) occurred in 4 cases [7, 32]. Moreover, AD-related pathology changes are frequently accompanied by changes related to vascular incidents [5, 27, 77] or other types of neurodegenerations, such as Lewy body pathology or other tauopathies [6, 32, 37, 74, 78]. Therefore, amyloid PET and its power for estimating AD pathology alone is, in our opinion, not sufficient for establishing the diagnosis of AD and needs to be supplemented by a neurological examination, magnetic resonance imaging to screen for vascular lesions, and p-τ biomarkers in order to confirm the diagnosis of AD, to identify specific variants such as the plaque predominant form of AD, and to detect non-AD tauopathies as it is part of the current recommendations for the clinical diagnosis of AD [49]. This is documented by cases in cohort 3 with advanced Aβ pathology with high PET-Aβ phase estimates and additional non-AD pathology (e.g. Lewy body disease). For disease progression monitoring on the other hand, PET-Aβ phase estimates of a single patient at different points in time could be a powerful tool to assess the speed of disease progression because of its close association with the neuropathological markers, especially the Aβ phase [67]. The transition from preclinical AD to the symptomatic stage correlated with a transition from Aβ phase 3 to 4 [71]. Since these Aβ phases can be assessed by the PET-Aβ phase estimates, amyloid PET can indicate patients at high risk for this transition. In advanced symptomatic AD, p-τ may be a better progression marker [30].

Another finding of this study is the correlation between the aspects of Aβ pathology with CAA, and the correlation of CAA severity and the topographical distribution of CAA with the PET-Aβ phase estimate. These data are in line with previous findings on the correlation between CAA and Aβ plaque deposition [68], the detectability of CAA cases by amyloid PET [14, 39] and its probable characteristics in the cortical tracer retention pattern [8, 19, 22]. However, it was also reported that CAA had no major impact on amyloid PET positivity because of the correlation between Aβ plaques and CAA [36]. Only single cases with predominant CAA and very limited amounts of plaques became detectable by amyloid PET as reported by others [20] and confirmed by one CAA-stage 3 case in our cohort 3 exhibiting Aβ phase 3 and Braak NFT-stage 0. This indicates that amyloid PET did not distinguish between Aβ plaque pathology and vascular Aβ deposition in CAA with the algorithms currently applied in a routine diagnostic setting. It just indicates whether Aβ deposits in a given amount are present or not whereby in most cases plaque pathology and CAA anyway correlate with one another. However, our findings also show single amyloid PET negative cases with CAA. Accordingly, we cannot confirm that amyloid PET is capable of ruling out CAA completely when negative as suggested by other authors [8] although indeed 16/20 amyloid PET negative cases in our study had no CAA. It may be important to note that one case with end-stage CAA (CAA distributed all over the brain) in our sample was amyloid PET negative. When assessing only positive/negative amyloid PET reads it had been reported that CAA may contribute to amyloid positivity in phase 3 cases [36] whereas analysis of the SUVRs allowed distinction between amyloid phases 0–2, 3, 4, and 5 in the same cohort of cases without interference with CAA [67].

Many reports showed that τ pathology precedes Aβ plaques neuropathologically [12, 16, 21, 65, 73]. In our three cohorts, we confirmed the presence of early stages of τ pathology in cases without Aβ plaques (Fig. 1) known as primary age-related tauopathy (PART) and to precede AD pathology [21]. Accordingly, our findings do not support the amyloid hypothesis in the sense that Aβ causes τ pathology [64]. However, the parallel increase of p-τ and Aβ pathology in the autopsy brains supports the hypothesis that Aβ can drive the propagation of pre-existing p-τ pathology as recently demonstrated in amyloid precursor protein transgenic mice [26, 28, 45, 53]. As such, our findings are in line with the hypothesis that prevalent τ pathology fulfilling the criteria of definite PART (= presence of NFTs in the absence of Aβ plaques) is a prerequisite for the development of AD and can be accelerated by the presence of Aβ aggregates finally leading to AD [65].

A limitation of this study is that there is no assessment of the B-Aβ stages and B-Aβ plaques stages in cohort 3 for comparison with the [18F]flutemetamol PET images. Since cohort 3 was recruited and studied in the context of a phase III clinical trial to determine the diagnostic value of [18F]flutemetamol, the assessment of AβN3pE presence or AβpSer8 presence was not considered in the study protocol. Correlation of the [18F]flutemetamol PET derived PET-Aβ phase estimates with the AβMTL phases and the Aβ load, i.e. a second parameter describing the topographical distribution of Aβ plaques (AβMTL phase) in addition to the Aβ phases and a quantitative parameter (Aβ load), support the hypothesis that the relationship between the three aspects of Aβ pathology as shown in cohort 1 is also valid for other cohorts of cases.

A second limitation of this study is the fact that we do not have an independent control group to confirm that the PET-Aβ phase estimates indeed correlate with the underlying Aβ phase. In addition to statistical analysis using bootstrapping methods as previously published [67], we determined a second parameter representing the topographical distribution of Aβ plaque pathology, the AβMTL phase, which is based on the assessment of a different set of brain regions in comparison to the Aβ phases [71, 72] and which also correlated very well with the PET-Aβ phase estimates. Moreover, another group of researchers demonstrated a similar amyloid PET-based distinction between the Aβ phases when using PIB-PET-derived centiloids to compare their cases [42]. [18F]flutemetamol shows, thereby, similar amyloid detection properties when compared with Pittsburg compound B (PIB) in clinical studies [33, 43] and similar increases in tracer retention with increasing Aβ phase [42, 67].


Our analysis of Aβ pathology in its topographical, quantitative and qualitative aspects (incl. CAA), in its relationship with other histopathological features of AD, cognitive decline and in its detection by amyloid PET in patients during life showed that all these parameters are correlated with one another. In doing so, the determination of one of these parameters seems to be sufficient for estimating the others, and for monitoring the progression of a once diagnosed symptomatic or preclinical disease. However, the occurrence of few cases (7.75% in our three cohorts) that lie outside of the general correlation, e.g., cases with plaque-predominant AD, argues against the use of only one parameter for establishing the diagnosis of AD. Since amyloid PET is the clinical biomarker, which is best validated by post-mortem end-of-life studies [15, 36, 42, 60, 67], and which allows estimation of the underlying neuropathological phase of Aβ deposition [67], amyloid PET seems to be ideally suited for this purpose especially for studying and determining the critical transition from preclinical to symptomatic AD as indicated by its correlation with the Aβ phases, Aβ loads, Braak NFT stages and the CERAD scores for neuritic plaque pathology.

Availability of data and materials

The anonymized datasets used and/or analyzed during the current study are stored in UZ/KU-Leuven network drives and available from the corresponding author on reasonable request.


  1. 1.

    Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I, Boluda S, Bugiani O, Duyckaerts C, Gelpi E, Gentleman S, Giaccone G, Graeber M, Hortobagyi T, Hoftberger R, Ince P, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Nilsson T, Parchi P, Patsouris E, Pikkarainen M, Revesz T, Rozemuller A, Seilhean D, Schulz-Schaeffer W, Streichenberger N, Wharton SB, Kretzschmar H (2009) Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe consortium. Acta Neuropathol 117(3):309–320

  2. 2.

    Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1):631–639

  3. 3.

    Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 42(9):1681–1688

  4. 4.

    Ashby EL, Miners JS, Kumar S, Walter J, Love S, Kehoe PG (2014) Investigation of Abeta phosphorylated at serine 8 (pAbeta) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. Neuropathol Appl Neurobiol 41:428–444.

  5. 5.

    Attems J, Jellinger KA (2014) The overlap between vascular disease and Alzheimer’s disease--lessons from pathology. BMC Med 12:206.

  6. 6.

    Attems J, Neltner JH, Nelson PT (2014) Quantitative neuropathological assessment to investigate cerebral multi-morbidity. Alzheimers Res Ther 6(9):85.

  7. 7.

    Bancher C, Jellinger KA (1994) Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathol 88(6):565–570

  8. 8.

    Baron JC, Farid K, Dolan E, Turc G, Marrapu ST, O'Brien E, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, Hong YT (2014) Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 34(5):753–758.

  9. 9.

    Beach TG, Thal DR, Zanette M, Smith A, Buckley C (2016) Detection of striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis 52(3):863–873.

  10. 10.

    Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404

  11. 11.

    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259

  12. 12.

    Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathological process in Alzheimer's disease: age categories 1 year to 100 years. J Neuropathol Exp Neurol 70:960–969

  13. 13.

    Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126(5):631–641.

  14. 14.

    Charidimou A, Farid K, Baron JC (2017) Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis. Neurology 89(14):1490–1498.

  15. 15.

    Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM, Group A-AS (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11(8):669–678.

  16. 16.

    Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, Mc Kee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL 3rd, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766.

  17. 17.

    Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S (2015) Phase 3 trial of Flutemetamol labeled with radioactive fluorine 18 imaging and Neuritic plaque density. JAMA Neurol 72:287–294.

  18. 18.

    DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14(1):32.

  19. 19.

    Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 68(4):545–548.

  20. 20.

    Ducharme S, Guiot MC, Nikelski J, Chertkow H (2013) Does a positive Pittsburgh compound B scan in a patient with dementia equal Alzheimer disease? JAMA Neurol 70(7):912–914.

  21. 21.

    Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. Acta Neuropathol 129(5):749–756.

  22. 22.

    Farid K, Hong YT, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, Baron JC (2015) Early-phase 11C-PiB PET in amyloid Angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value? PLoS One 10(10):e0139926.

  23. 23.

    Folstein MF, Folstein SE, McHugh PR (1975) “mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198

  24. 24.

    Gerth J, Kumar S, Rijal Upadhaya A, Ghebremedhin E, von Arnim CAF, Thal DR, Walter J (2018) Modified amyloid variants in pathological subgroups of beta-amyloidosis. Ann Clin Transl Neurol 5(7):815–831.

  25. 25.

    Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–890

  26. 26.

    Gomes LA, Hipp SA, Rijal Upadhaya A, Balakrishnan K, Ospitalieri S, Koper MJ, Largo-Barrientos P, Uytterhoeven V, Reichwald J, Rabe S, Vandenberghe R, von Arnim CAF, Tousseyn T, Feederle R, Giudici C, Willem M, Staufenbiel M, Thal DR (2019) Abeta-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol.

  27. 27.

    Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42(9):2672–2713.

  28. 28.

    Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534):1491–1495.

  29. 29.

    Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112

  30. 30.

    Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K (2019) Association of Amyloid and tau with Cognition in preclinical Alzheimer Disease: a longitudinal study. JAMA Neurol.

  31. 31.

    Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vanini P, Donovan NJ, Chhatwal JP, Marshall GA, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA, Alzheimer’s Disease Neuroimaging I, Harvard Aging Brain S (2018) PET staging of amyloidosis using striatum. Alzheimers Dement 14(10):1281–1292.

  32. 32.

    Hansen LA, Masliah E, Galasko D, Terry RD (1993) Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol 52(6):648–654.

  33. 33.

    Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H (2014) [18F] Flutemetamol amyloid-beta PET imaging compared with [11C] PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging 41(2):290–300.

  34. 34.

    Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572

  35. 35.

    Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13

  36. 36.

    Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M, Mathis CA, Klunk WE, Chakrabarty A, Ironside J, Ismail A, Smith C, Thal DR, Beach TG, Farrar G, Smith AP (2016) Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun 4(1):130.

  37. 37.

    Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598.

  38. 38.

    Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of a beta 42(43) and a beta 40 in senile plaques with end-specific a beta monoclonals: evidence that an initially deposited species is a beta 42(43). Neuron 13(1):45–53

  39. 39.

    Jang H, Jang YK, Kim HJ, Werring DJ, Lee JS, Choe YS, Park S, Lee J, Kim KW, Kim Y, Cho SH, Kim SE, Kim SJ, Charidimou A, Na DL, Seo SW (2019) Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging 46(6):1287–1298.

  40. 40.

    Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J (2013) Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. Acta Neuropathol 125(5):699–709.

  41. 41.

    Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271(8):4077–4081.

  42. 42.

    La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Dore V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD (2018) Multisite study of the relationships between antemortem [(11) C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement.

  43. 43.

    Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, Pontecorvo M, Baker SL, Jagust WJ, Alzheimer’s Disease Neuroimaging I (2014) Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41(7):1398–1407.

  44. 44.

    Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3(1):16–32

  45. 45.

    Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534):1487–1491

  46. 46.

    Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3):853–862

  47. 47.

    Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82(12):4245–4249

  48. 48.

    Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133(Pt 5):1328–1341

  49. 49.

    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269.

  50. 50.

    McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6):860–866

  51. 51.

    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's Disease (CERAD). Part II Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479–486

  52. 52.

    Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR Jr, Dickson DW (2015) Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 138(Pt 5):1370–1381.

  53. 53.

    Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3):321–332.

  54. 54.

    Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12(4):295–312

  55. 55.

    Rezaei-Ghaleh N, Amininasab M, Kumar S, Walter J, Zweckstetter M (2016) Phosphorylation modifies the molecular stability of beta-amyloid deposits. Nat Commun 7:11359.

  56. 56.

    Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fändrich M, Staufenbiel M, Thal DR (2012) Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging 33:2641–2660

  57. 57.

    Rijal Upadhaya A, Kosterin I, Kumar S, Von Arnim C, Yamaguchi H, Fändrich M, Walter J, Thal DR (2014) Biochemical stages of amyloid β-peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically-preclinical Alzheimer’s disease. Brain 137:887–903

  58. 58.

    Rijal Upadhaya A, Lungrin I, Yamaguchi H, Fändrich M, Thal DR (2012) High-molecular weight Aβ-oligomers and protofibrils are the predominant Aβ-species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16:287–295

  59. 59.

    Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li QX, Ryan TM, McLean CA, Doecke JD, Rowe CC, Villemagne VL, Masters CL (2017) Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET. Brain 140(5):1486–1498.

  60. 60.

    Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ, Florbetaben Phase 3 Study G (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement.

  61. 61.

    Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, a beta N3(pE), in senile plaques. Neuron 14(2):457–466

  62. 62.

    Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C (2017) Performance of [(18) F] flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst) 9:25–34.

  63. 63.

    Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU (2009) Pyroglutamate formation influences solubility and Amyloidogenicity of amyloid peptides. Biochemistry 48:7072–7078

  64. 64.

    Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8(6):595–608.

  65. 65.

    Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134(2):187–205.

  66. 66.

    Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP, Buckley C (2015) [18F] flutemetamol amyloid PET in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of Aβ pathology. Alzheimers Dement 11:975–985

  67. 67.

    Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL (2018) Estimation of amyloid distribution by [(18) F] flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition. Acta Neuropathol 136(4):557–567.

  68. 68.

    Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular pathology in Alzheimer’s disease: correlation of cerebral amyloid angiopathy and arteriosclerosis / lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62(12):1287–1301

  69. 69.

    Thal DR, Griffin WS, Braak H (2008) Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 12(5B):1848–1862

  70. 70.

    Thal DR, Hartig W, Schober R (1998) Stage-correlated distribution of type 1 and 2 dystrophic neurites in cortical and hippocampal plaques in Alzheimer's disease. J Hirnforsch 39(2):175–181

  71. 71.

    Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800

  72. 72.

    Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59(8):733–748

  73. 73.

    Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J, Rijal Upadhaya A (2013) Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 263(Suppl 2):S137–S145.

  74. 74.

    Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J, Arzberger T (2015) Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. J Neural Transm.

  75. 75.

    Thal DR, Walter J, Saido TC, Fandrich M (2015) Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease. Acta Neuropathol 129:167–182.

  76. 76.

    Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, Sherwin P (2014) Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 55(10):1623–1628.

  77. 77.

    Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's coordinating Centre. Brain 136(Pt 9):2697–2706.

  78. 78.

    Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, Lee EB, Arnold SE, Duda JE, Hurtig H, Lee VM, Adler CH, Beach TG, Trojanowski JQ (2016) Pathological alpha-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol 131(3):393–409.

  79. 79.

    Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68(3):319–329.

  80. 80.

    Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 30(5):637–649.

  81. 81.

    Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 158(2):328–337.

Download references


Sample preparation, histology and immunohistochemical staining for cohort 3 was performed by Covance Laboratories, Harrogate, UK. The authors thank Uta Enderlein, Nicole Kolosnjaji, Kathrin Pruy, Irina Kosterin, and Christine Schneider for technical help for cohort 1, and Simona Ospitalieri and Petra Weckx for cohort 2.


The data of cohort 3 which is published in this manuscript was derived from subjects in the GE-Healthcare sponsored studies: GE-067-007 and GE-067-026 (GF) ( The data of cohort 1 were collected in projects funded by the Deutsche Forschungsgemeinschaft (TH624 4–1, 4–2, 6–1 (DRT), WA1477 6–2 (JW)) and the Alzheimer Forschung Initiative (#10810, #13803 (DRT), #12854, #17011 (S.K.)). The data of cohort 2 were collected in projects funded by Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO- G0F8516N Odysseus (DRT, RV)) and Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043 (RV, DRT)).

Author information

Study design and coordination: all cohorts: DRT, only cohort 1: JW, only cohort 3: CB, APLS, GF; Manuscript preparation: DRT; Neuropathology: all cohorts DRT, only cohort 2: TT, only cohort 3: TGB, AC, AI; Immunohistochemistry and evaluation: all cohorts DRT, only cohort 1 and 2: AR, only cohort 1: ARU, KB, SK, JW; Biochemistry – cohort 1: ARU, KB, SK, JW; Clinical assessments: only cohort 1: CAFvA, MO, only cohort 2: RV, MV; clinical data collection cohort 3: CB, APLS, GF; PET analysis/ PET data analysis cohort 3: JL, KH, CB, APLS, GF, only determination of PET-Aβ phase estimates DRT; Statistical analysis: DRT; manuscript review: AR, TT, AJR, KB, RV, MV, CAFvA, MO, TGB, JL, KH, AC, AI, CB, APLS, SK, GF, JW. All authors read and approved the final manuscript.

Correspondence to Dietmar Rudolf Thal.

Ethics declarations

Ethics approval and consent to participate

All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases from cohort 1 was granted by the ethical committee of Ulm University (Germany), and for the cohort 2 cases by the UZ/KU-Leuven ethical committee (Belgium). Cohort 3 was obtained for the efficacy analysis of the [18F] flutemetamol phase III autopsy study ( identifiers NCT01165554, and NCT02090855) [9, 36]. Local institutional review boards or ethics committees approved the study protocols before initiation [17, 66]. This study covering the retrospective analysis of samples and data from the three cohorts was approved by the UZ/KU-Leuven ethical committee (S-59295) (Belgium).

Consent for publication

Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.

Competing interests

DRT received consultancies from GE-Healthcare (UK) and Covance Laboratories (UK), speaker honorarium from Novartis Pharma Basel (Switzerland), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany), and Janssen Pharmaceutical Companies (Belgium). TGB received a consultancy from GE-Healthcare (UK). GF, CB, APLS are employees of GE-Healthcare (UK, USA). JL and KH were employees of GE-Healthcare (Sweden). JL is currently employee of Hermes Medical Solutions (Sweden). AC and AI received personal fees from GE-Healthcare via the University of Leeds. CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Hongkong University Research council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2018) and Dr. Willmar Schwabe GmbH &Co. KG (2014–2015). MO received honoraria from serving on the advisory board of Axon and Fujirebio.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Table S1. List of antibodies and silver techniques. IHC = immunohistochemistry, WB = western blotting. Table S2. Assessment of topographical distribution of Aβ plaques (a-d), CAA (a, e), and CAA severity [80] (a, f). Tissue-block selection (a) and assessment of Aβ phases (b) [71], AβMTL phases (c) [72], A-scores (d) [35], CAA stages (e), and the CAA severity degree according to Vonsattel et al. [80] (f). Table S3. Assessment of the biochemical Aβ stage of plaque maturation (=B-Aβ plaque stage; a) and the biochemical stage of Aβ aggregate maturation in brain lysates (B-Aβ stage; b). Table S4. Assessment of PET-Aβ phase estimates as previously published [67]. Table S5. Spearman correlation analysis between Aβ phases, AβMTL phases, A-scores, and Aβ load as assessed in cohorts 1 (a), 2 (b), and 3 (c) as well as AβN3pE load, AβpSer8 load, B-Aβ stage, B-Aβ plaque stage, and the levels of soluble, dispersible, membrane-associated and plaque-associated Aβ, AβN3pE, and AβpSer8 in cohort 1. r and p-values are provided. No adjustment for age and sex because different methods assessing Aβ pathology were compared. n = number of cases compared. Table S6. Spearman correlation analysis between PET-Aβ phase estimates, topographical and quantitative Aβ parameters assessed in cohort 3. No adjustment for age and sex because different methods assessing Aβ pathology were compared. n = number of cases compared. Table S7. Partial correlation analysis controlled for age and sex between NFT stages, CERAD scores of neuritic plaque pathology, NIA-AA degree of AD pathology, CDR-scores, Aβ phases, AβMTL phases, A-scores, and Aβ load as assessed in cohorts 1 (a), 2 (b), and 3 (c) as well as AβN3pE load, AβpSer8 load, B-Aβ stage, B-Aβ plaque stage, and the levels of soluble, dispersible, membrane-associated and plaque-associated Aβ, AβN3pE, and AβpSer8 in cohort 1. r and p-values are provided. n = number of cases compared.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thal, D.R., Ronisz, A., Tousseyn, T. et al. Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. acta neuropathol commun 7, 178 (2019).

Download citation


  • Alzheimer’s disease
  • Amyloid β peptide
  • Staging
  • Amyloid load
  • Soluble amyloid
  • Insoluble amyloid
  • Amyloid maturation
  • Amyloid PET
  • [18F]flutemetamol